정규장
로그인 회원가입
RMD
Resmed Inc
7월 27일 1:45 PM ET (한국 7/28 02:45)
$195.27
+3.38 ▲ +1.76%

레스메드(RMD) is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.

시황 · 실적발표 · 매수매도 신호, 가장 먼저 받아보세요 🔔 구독
시가총액
$28.3B
미드캡
P/E
18.8
적정 수준
배당수익률
1.25%
52주 위치
13%
저점 +8% · 고점 -34%
애널리스트
매수
B-
Fundamental health
vs. Medical Instruments & Supplies
수익성 ⓘ
Top 11%
성장 ⓘ
Top 32%
밸류에이션 ⓘ
Top 60%
재무 안정 ⓘ
Top 52%
💰 Is this stock pricier than usual right now? ⓘ
Compared to this company's own recent 5년 (not other companies).
💎 Very cheap
Cheap
Typical
Pricey
Very pricey
Simply put — what you pay today to own $1 of this company's yearly earnings is 19원. Over the past 5년, it usually traded around 32원. One of the cheapest stretches of the past 5년.
Pricy doesn't mean bad — it means expectations are already baked in.
Index ⓘ S&P 500P/E ⓘ 18.82EPS (ttm) ⓘ 10.37Insider Own ⓘ 0.93%Shs Outstand ⓘ 145.0MPerf Week ⓘ -1.87%
Market Cap ⓘ 28.33BForward P/E ⓘ 16.19EPS next Y ⓘ 8.38%Insider Trans ⓘ -2.81%Shs Float ⓘ 143.7MPerf Month ⓘ -0.63%
Enterprise Value ⓘ 27.50BPEG ⓘ 1.4EPS next Q ⓘ 2.89Inst Own ⓘ 74.8%Short Float ⓘ 10.51%Perf Quarter ⓘ -11.04%
Income ⓘ 1.52BP/S ⓘ 5.11EPS this Y ⓘ 16.5%Inst Trans ⓘ -0.61%Short Ratio ⓘ 9.71Perf Half Y ⓘ -23.53%
Sales ⓘ 5.54BP/B ⓘ 4.36EPS next 5Y ⓘ 11.56%ROA ⓘ 18.59%Short Interest ⓘ 15.10MPerf YTD ⓘ -18.93%
Book/sh ⓘ 44.76P/C ⓘ 17EPS past 3/5Y ⓘ 21.5% 17.37%ROE ⓘ 25.25%52W High ⓘ -33.54% ($293.81)Perf Year ⓘ -28.6%
Cash/sh ⓘ 11.49P/FCF ⓘ 16.15Sales past 3/5Y ⓘ 12.88% 11.72%ROIC ⓘ 21.57%52W Low ⓘ 8.32% ($180.26)Perf 3Y ⓘ -10.49%
Dividend Est. ⓘ $2.43 (1.25%)EV/EBITDA ⓘ 12.57EPS Y/Y TTM ⓘ 16.4%Gross Margin ⓘ 60.74%Volatility(W/M) ⓘ 2.17% 2.88%Perf 5Y ⓘ -24.85%
Dividend TTM ⓘ 2.4EV/Sales ⓘ 4.97Sales Y/Y TTM ⓘ 10.28%Oper. Margin ⓘ 34.76%ATR (14) ⓘ 6.24Perf 10Y ⓘ 196.18%
Dividend Ex-Date ⓘ 2026/5/14Quick Ratio ⓘ 2.33EPS Q/Q ⓘ 10.35%Profit Margin ⓘ 27.44%RSI (14) ⓘ 46.17Recom ⓘ 2
Dividend Gr. 3/5Y ⓘ 8.06% 6.33%Current Ratio ⓘ 3.01Sales Q/Q ⓘ 10.81%SMA20 ⓘ -3.02% ($201.35)Beta ⓘ 0.77Target Price ⓘ $262.91
Payout ⓘ 22.3%Debt/Eq ⓘ 0.13Earnings ⓘ 2026/8/6SMA50 ⓘ -1.71% ($198.67)Rel Volume ⓘ 0.65Prev Close ⓘ $191.89
Employees ⓘ 10600LT Debt/Eq ⓘ 0.09EPS/Sales Surpr. ⓘ 2.31% 0.81%SMA200 ⓘ -16.45% ($233.72)Avg Volume(3M) ⓘ 1.56MPrice ⓘ $195.27
IPO ⓘ 1995/6/2Option/Short ⓘ Yes/YesTrades ⓘ 14816Volume ⓘ 1,005,225Change ⓘ 1.76%
Quarterly earnings trend SEC filings · USD
24.6*
24.9
24.12
25.3
25.6*
25.9
25.12
26.3
Revenue Net income 최근 분기: 매출 $1.4B (YoY +11%) · 순이익 $399M (YoY +9%)
* Q4 figures are derived from the annual filing (10-K) · loss-making quarters are underlined in red

📊 Resmed Inc (RMD) Investment Analysis

What kind of company is Resmed Inc?

레스메드(RMD) 방어주
Healthcare · Medical Instruments & Supplies
Top 487 by Market Cap — Large-Cap

A global medical device company specializing in software-based digital health solutions for sleep apnea and respiratory diseases. Founded in 1989 in Sydney, Australia, the company is headquartered in California, USA, and serves as a key part of a global respiratory medical device group, supplying CPAP devices, masks, and respiratory equipment for sleep apnea (OSA) as well as chronic care software.

Learn more about Resmed Inc →
Market Cap
$28.3B
Approx. KRW 38.8 trillion
⚖️ 10% of Samsung Electronics
Market Cap Rank487
Employees10,600people
IPO1995/06/02
Current Price$195.27 ≈ 267,520원
📌 S&P 500 · NYSE · USA

Key Events

⏰ Upcoming events
🔔 Earnings release D-10
8월 6일 (목) · 장 마감 후
예상 EPS $2.89
🎯 Ex-dividend date
No scheduled dividends
📜 Recent events
🎯 Ex-div 2026년 5월 14일 (목) 주당 $0.6
🔔 Earnings release 2026년 4월 30일 (목) · 장 마감 후 EPS +2.3% 매출 +0.8%
🎯 Ex-div 2026년 2월 12일 (목) 주당 $0.6

Is it profitable?

Solid company — profitability & finances both healthy
Strong earnings and excellent financial health
Profitability — How efficiently it makes money
Operating Margin
Profit kept from selling products and services (higher is better)
34.8%
✓ 우수
My positionTop 5%
Low range Average High range
Medical Instruments & Supplies Median 5.5% · Top tier
💡 일반적으로 10% 이상이면 양호, 20% 이상이면 우수
Net Margin
Share of revenue left after taxes and interest are paid
27.4%
✓ 우수
My positionTop 5%
Low range Average High range
Medical Instruments & Supplies Median -5.3% · Top tier
💡 일반적으로 8% 이상이면 양호, 15% 이상이면 우수
Gross Margin
Profit after subtracting raw-material costs only (signals product competitiveness)
60.7%
✓ 우수
My positionTop 25%
Low range Average High range
Medical Instruments & Supplies Median 48.6% · Top 24%
💡 제조업 30%, IT/소프트웨어 50% 이상이면 우수 (업종별 편차 큼)
ROE
Annual return earned on shareholders' equity (15%+ is strong)
25.3%
✓ 우수
My positionTop 25%
Low range Average High range
Healthcare 대형주 Median 11.9% · Top 24%
💡 일반적으로 15% 이상이면 우수 (단, 부채 레버리지 효과 주의)
ROA
Annual earnings relative to total company assets
18.6%
✓ 우수
My positionTop 5%
Low range Average High range
Healthcare 대형주 Median 5.1% · Top 5%
💡 일반적으로 5% 이상이면 양호, 10% 이상이면 우수
ROIC
Return generated per dollar invested in the business
21.6%
✓ 우수
My positionTop 25%
Low range Average High range
Healthcare 대형주 Median 7.4% · Top 12%
💡 자본비용(보통 8~10%)보다 높으면 가치 창출, 15% 이상이면 우수
Financial health — Debt & liquidity burden
Debt-to-Equity (D/E)
Debt relative to equity (lower is healthier)
0.13
✓ Healthy debt
My positionMid-range
Low range Average High range
Medical Instruments & Supplies Median 0.26
💡 일반적으로 1.0 이하면 건전, 1.5까지는 무난 (금융·유틸·REIT는 구조적으로 높음)
Current Ratio
Liquid assets available to cover liabilities due within a year
3.01
✓ 양호
My positionMid-range
Low range Average High range
Medical Instruments & Supplies Median 2.34
💡 1.5~3.0 적정, 1.0 미만이면 단기 유동성 주의
Quick Ratio
Liquid assets excluding inventory, available for immediate use
2.33
✓ 양호
My positionMid-range
Low range Average High range
Medical Instruments & Supplies Median 1.97
💡 1.0 이상이면 안전, 0.5 미만이면 주의
* Ratings reflect relative position vs. peer-group distribution (same sector & size) plus absolute guards (loss & risk thresholds).

What's the outlook?

Mixed Outlook
Positive and negative signals are mixed
애널리스트 목표가
$262.91
현재가 대비 +34.6%
💡 12개월 이내 도달을 전망하는 애널리스트 컨센서스 평균
예상 PER (Forward)
16.19배
💡 내년 예상 EPS 기준. 현재 PER과 비교해 이익 성장 반영 정도 확인
PEG (성장 반영 밸류)
1.40
적정
💡 PEG 1~1.5 — 성장 대비 합리적
내년 EPS 예상 성장률
+8.4%
💡 10% 이상이면 견조한 성장, 마이너스는 이익 감소 예상
5년 EPS 예상 연평균
+11.6%
💡 장기 성장 전망. 15% 이상이면 고성장 기업
⚠ 이 데이터는 애널리스트 추정치이며 실제 결과와 다를 수 있습니다. 투자 결정은 추가 검토와 함께 하세요.

Did earnings meet expectations?

High Earnings Reliability
Beat estimates in 1 of the last 1 quarters
1
예상 상회
0
예상 부합
0
예상 하회
100%
상회 비율
+2.1%
평균 서프라이즈
2026.04.30
상회
실적 $2.86 · 예상 $2.80 +2.1%
💡 예상보다 높은 실적을 자주 내는 기업은 실적 신뢰도가 높다고 평가됩니다. 단, 애널리스트 기대치가 낮게 설정되었을 수도 있으니 절대 수치도 함께 봐야 합니다.

Is it growing?

Average Growth
Mid-range within the industry
Healthy, Balanced Growth EPS and revenue are both growing steadily — a sustainable growth profile
🔮 How much will it grow? (analyst forecasts)
This Year's EPS Outlook
Projected EPS growth rate for this year
+16.5%
우수
My positionTop 25%
Low range Average High range
방어주 대형주 Median 9.6% · Top 20%
Next Year's EPS Outlook
Projected EPS growth rate for next year (analyst consensus)
+8.4%
부진
My positionBottom 25%
Low range Average High range
방어주 대형주 Median 10.8% · Bottom 22%
5-Year EPS CAGR Outlook
Projected average annual EPS growth over the next 5 years
+11.6%
양호
My positionMid-range
Low range Average High range
방어주 대형주 Median 9.8% · Top 34%
📊 How much has it grown? (actual results)
Past 3-Year EPS
Actual average annual EPS growth over the past 3 years
+21.5%
우수
My positionTop 25%
Low range Average High range
방어주 대형주 Median 4.7% · Top 23%
Past 5-Year EPS
Actual average annual EPS growth over the past 5 years
+17.4%
우수
My positionTop 25%
Low range Average High range
방어주 대형주 Median 4.1% · Top 8%
Past 5-Year Revenue
How much revenue grew over the past 5 years
+11.7%
우수
My positionTop 25%
Low range Average High range
방어주 대형주 Median 6.7% · Top 23%
⚡ Short-term momentum
QoQ Revenue
Revenue change from the previous quarter (short-term momentum)
+10.8%
양호
My positionMid-range
Low range Average High range
방어주 대형주 Median 8.4% · Top 41%
* Forecast values are analyst consensus estimates. Ratings are determined by relative position vs. peer group of the same growth style and size.
New to investing terms? Look it up in the financial dictionary →

Has the stock risen over the long term?

Long-term weakness — -93%p below the market
RMD -24.9% · S&P 500 +68.0%
Excess return vs. market (price-based, ex-dividends)
5-year basis
vs S&P 500
-92.8%p
Significantly behind the market
vs Health Care (XLV)
-48.5%p
Significantly behind the sector average
1-year basis
vs S&P 500
-45.1%p
Significantly behind the market
vs Health Care (XLV)
-48.4%p
Significantly behind the sector average
Current position within 52-week range
Low (-8.3%p) High (-33.5%p)
Current price is 8.3% above the 52-week low and 33.5% below the 52-week high
Recent risk (last 120 trading days)
Max drawdown
-33.8%
Annualized volatility
32.8%

Technical Indicators

Bollinger Bands · MACD · RSI · Stochastics · Ichimoku 5-line · recent 136-day series

Price · Bollinger Bands · Ichimoku Cloud

  • close
  • BB Upper
  • BB Mid
  • BB Lower
  • Tenkan
  • Kijun
  • Cloud (SpanA/B)

Bollinger Bands are upper and lower channels showing the closing price range (20 days · 2σ). Touching the upper band = overheated; touching the lower band = oversold. Ichimoku Cloud shows trend direction and strength through colored areas. Prices above the cloud indicate an uptrend; prices below indicate a downtrend. About Bollinger Bands →

🔴
Current diagnosis · 2026-07-24
Downtrend zone

Current price $195.27 below the midline ($201.35). Normal downward flow. Below the Ichimoku cloud (bearish).

MACD (12 · 26 · 9) Expand ▼

An indicator that uses the difference between the short-term EMA (12) and long-term EMA (26) to identify trend reversals. When MACD rises above the Signal line, it is a buy signal (golden cross); when it falls below, it is a sell signal (death cross). About MACD →

🔴
Current diagnosis · 2026-07-24
Bearish momentum holding

MACD -1.421 < Signal -0.290 in negative zone + Hist negative (-1.131). Weakness in progress.

RSI(14) · Stochastics %K(14) Expand ▼

RSI measures short-term buying and selling pressure on a scale of 0–100. 30 or below = oversold (a rebound may be possible); 70 or above = overbought (a pullback may be possible). Stoch %K similarly measures short-term momentum strength. RSI · Learn more about Stochastics →

🔴
Current diagnosis · 2026-07-24
Bearish zone

RSI 46.2 (below the neutral level of 50). Selling pressure leads, indicating a weak trend. Stoch %K is also 17.0.

※ "Current diagnosis" is an automated interpretation based on standard thresholds and is for reference only. Make your own comprehensive judgment before trading.

Is it attractive at this price?

Cheaper than peers in its industry
Cheap on Vs. Earnings·Vs. Cash Flow, Pricey on Vs. Assets, In line with peers on Vs. Sales
💡 How to read this — Compare against peers in the same industry to see what the price is cheap or expensive relative to. Example: cheap vs. earnings = stock price is low relative to what the company earns; expensive vs. assets = stock price is high relative to assets on the balance sheet.
💵 Vs. Earnings Cheap
🏢 Vs. Assets Pricey
🧾 Vs. Sales Mid-range
💧 Vs. Cash Flow Cheap
💵 Vs. Earnings
PER Price-to-Earnings Ratio
How expensive the price is vs. earnings — lower is cheaper
18.82x
✓ Very cheap
My positionTop 25%
Low range Average High range
Medical Instruments & Supplies median 35.22x · Top 22% — relatively cheap within the industry
💡 PER 15 이하 저평가, 25 이상이면 성장성 검증 필요 (적자 기업은 의미 없음)
💵 Vs. Earnings
Forward PER Forward Price-to-Earnings Ratio
PER using next year's estimated earnings — reflects growth
16.19x
✓ Cheap
My positionMid-range
Low range Average High range
Medical Instruments & Supplies median 18.44x · Around the industry average
💡 향후 12개월 예상 EPS 기준 PER. 현재 PER보다 낮으면 이익 성장 중
🏢 Vs. Assets
PBR Price-to-Book Ratio
Price vs. the company's asset value — below 1 trades cheaper than assets
4.36x
✓ Pricey
My positionBottom 25%
Low range Average High range
Medical Instruments & Supplies median 2.71x · Bottom 24% — expensive within the industry
💡 PBR 1 미만이면 청산가치 이하 (금융·제조업에서 특히 의미, IT는 낮은 비중)
🧾 Vs. Sales
PSR Price-to-Sales Ratio
Market cap vs. revenue — lower is cheaper relative to sales
5.11x
✓ Fair
My positionMid-range
Low range Average High range
Medical Instruments & Supplies median 2.92x · Around the industry average
💡 PSR 2 이하 저평가, 10 초과면 고평가 (고성장 기업일 때만 정당화)
💧 Vs. Cash Flow
EV/EBITDA Enterprise Value Multiple
Total enterprise value ÷ operating cash earnings — a benchmark for M&A
12.57x
✓ Cheap
My positionMid-range
Low range Average High range
Medical Instruments & Supplies median 14.76x · Around the industry average
💡 EV/EBITDA 10 이하 저평가, 20 이상이면 고평가 (M&A 밸류 기준)
💧 Vs. Cash Flow
P/FCF Price-to-Free-Cash-Flow Ratio
Price vs. actual cash generation — lower means more efficient
16.15x
✓ Very cheap
My positionTop 25%
Low range Average High range
Medical Instruments & Supplies median 25.16x · Top 11% — relatively cheap within the industry
💡 P/FCF 20 이하면 현금창출 대비 저평가 (실질 수익성 기준)
Analyst target price (reference)
$262.91 vs. current price +34.6%
* Valuation is the stock's relative position within the industry peer group (same sector and market-cap range). Even when valuation looks attractive, check the 'Profitability' and 'Growth' sections too.
As of: Recent snapshot · Peer group: Medical Instruments & Supplies

Who owns it?

Ownership backdrop is unfavorable
Insider modest net selling -2.8% · Institutional modest net selling -0.6% · Short interest elevated 10.5% · Short interest up +2.3pp over last 90d
📈 Recent trading flow (6 months)
🧑‍💼 Insiders (executives & directors)
-2.8%
Insiders net selling
🏦 Institutions (funds & investors)
-0.6%
Institutions net selling
💡 Net change over the past 6 months. Shows how much insiders and institutions increased or reduced their holdings, in %.
👥 Holdings composition
🏦 Institutions 74.8%
Adequate institutional weight
Healthcare 대형주 Median 91.9%
🧑‍💼 Insiders 0.9%
Low, common among large-caps
Healthcare 대형주 Median 0.8%
👤 Retail investors (estimated) 24.3%
Everyone excluding institutions and insiders
Institutions Insiders Retail (est.)
📉 Short-selling metrics
Short ratio
10.5%
Somewhat high
Healthcare 대형주 Median 3.6%
Past 90 days 📈 +2.3%p increase
Short interest days to cover
9.7 days
Days needed to close short positions using average trading volume
🧮 Share count
Total shares outstanding 145.0M주
Float (tradable shares) 143.7M주
* Insider/institutional flows are based on net changes over the past 6 months. Trend is cumulative over the past 90 days.

ETFs holding RMD

ETFs with the highest weightings · 10 total shown
LGHT
LGHT
Langar Global HealthTech ETF
8.82%
$2M
EKG
EKG
First Trust Nasdaq Lux Digital Health Solutions ETF
7.75%
$4M
HEAL
HEAL
Global X HealthTech ETF
4.63%
$28M
IHI
IHI
iShares U.S. Medical Devices ETF
4.43%
$2.9B
CWS
CWS
AdvisorShares Focused Equity ETF
3.94%
$130M
* Based on official quarterly filings. Latest disclosure; actual current weights may differ.

How much does it pay in dividends?

배당 지급 — 연 1.25%
배당보다 주가 성장에 가까운 비중
Dividend Yield
1.25%
Industry average 1.25%
Dividend Per Share
$2.43
Annualized
Payout Ratio
22%
Share of net income paid as dividends
5-Year Growth
6.3%
Annualized dividend growth
🏆 13년 연속 배당 증가
📅 지급월 2월 · 8월 · 11월
📊 총 이력 2012~2026 (55건)
연도별 배당 총액 추이
주당 배당금을 연 단위로 합산한 금액입니다. 막대가 우상향이면 매년 배당이 늘어나고 있다는 뜻입니다.
$1.26 +8.6%
2016
$1.36 +7.9%
2017
$1.44 +5.9%
2018
$1.52 +5.6%
2019
$1.56 +2.6%
2020
$1.62 +3.8%
2021
$1.72 +6.2%
2022
$1.84 +7.0%
2023
$2.02 +9.8%
2024
$2.26 +11.9%
2025
$X.XX 그 해 총 배당금 +X% 전년 대비 증가 -X% 감소
최근 배당 이력 총 55건
아래로 스크롤하면 과거 배당 이력을 볼 수 있습니다.
배당락일
주당 금액
지급일
당시 수익률
2026-02-12
$0.600
—
1.16%
2025-11-13
$0.600
—
0.90%
2025-08-14
$0.600
—
0.96%
2025-05-08
$0.530
—
1.07%
2025-02-13
$0.530
—
0.86%
2024-11-07
$0.530
—
1.01%
2024-08-15
$0.530
—
1.08%
2024-05-08
$0.480
—
1.11%
2024-02-07
$0.480
—
1.24%
2023-11-08
$0.480
—
1.53%
2023-08-16
$0.480
—
1.29%
2023-05-10
$0.440
—
0.93%
2023-02-08
$0.440
—
0.98%
2022-11-09
$0.440
—
1.01%
2022-08-17
$0.440
—
0.90%
2022-05-11
$0.420
—
1.08%
2022-02-09
$0.420
—
0.83%
2021-11-09
$0.420
—
0.77%
2021-08-18
$0.420
—
0.71%
2021-05-12
$0.390
—
1.01%
2021-02-10
$0.390
—
0.97%
2020-11-10
$0.390
—
0.74%
2020-08-19
$0.390
—
0.85%
2020-05-13
$0.390
—
0.95%
2020-02-12
$0.390
—
0.89%
2019-11-06
$0.390
—
1.32%
2019-08-14
$0.390
—
1.43%
2019-05-08
$0.370
—
1.64%
2019-02-06
$0.370
—
1.89%
2018-11-07
$0.370
—
1.66%
2018-08-15
$0.370
—
1.65%
2018-05-09
$0.350
—
1.76%
2018-02-07
$0.350
—
1.85%
2017-11-08
$0.350
—
2.06%
2017-08-15
$0.350
—
2.31%
2017-05-09
$0.330
—
2.40%
2017-02-07
$0.330
—
2.31%
2016-11-08
$0.330
—
2.71%
2016-08-16
$0.330
—
2.21%
2016-05-17
$0.300
—
2.59%
2016-02-09
$0.300
—
2.55%
2015-11-17
$0.300
—
2.50%
2015-08-18
$0.300
—
2.59%
2015-05-19
$0.280
—
1.97%
2015-02-10
$0.280
—
2.10%
2014-11-18
$0.280
—
2.03%
2014-08-19
$0.280
—
2.00%
2014-05-16
$0.250
—
2.31%
2014-02-14
$0.250
—
2.38%
2013-11-15
$0.250
—
1.98%
2013-08-16
$0.250
—
1.88%
2013-05-17
$0.170
—
1.36%
2013-02-14
$0.170
—
1.18%
2012-11-16
$0.170
—
0.87%
2012-09-05
$0.170
—
0.44%
* "배당락일"은 배당받으려면 이 날 이전에 주식을 보유해야 하는 기준일입니다. 지급일·당시 수익률은 일부 종목에서 데이터가 없을 수 있습니다.
💰 내가 100만원 투자한다면
연간 배당금 (세후) 1.1만원
5년 누적 (세후) 6.0만원
* 환율 1,370원, 세금 15% 반영. 5년 누적은 배당 성장률 연 6.33% 가정.

Compare Industry Peers

💡 vs. sector average ▲ Favorable / ▼ Unfavorable (Lower PER and PBR are better; higher ROE and dividend yield are better)
Sorted by market cap, largest first
StockMarket CapPERPBRROEDividend YieldChange
RMD This Stock
$28.3B18.8 ▲4.4 ▼25.25% ▲1.25% +1.8%
LLY
$1.13T43.0 ▼36.2 ▼107.64% ▲0.58% ▼+0.9%
JNJ
$634.1B30.5 ▼7.5 ▼25.74% ▲2.04% ▲+1.6%
ABBV
$458.2B127.9 ▼- 15221.82% ▲2.65% ▲+0.9%
UNH
$382.1B27.1 ▼3.9 ▼12.49% ▲2.15% ▲-0.7%
MRK
$323.7B36.9 ▼7.1 ▼18.97% ▲2.49% ▲+0.5%
Sector Avg-25.82.7-48.83%1.25%-
📊
See the market at a glance with a real-time dashboard Track premarket, regular, and after-hours quotes, screeners, and heatmaps on a single screen
→

Related News & Content

📖 Company overview
레즈메드(RMD) 뭐하는 회사일까? - 주가 전망·실적·시총·관련주·본사 총정리
레즈메드(RMD)는 수면 무호흡·호흡기 질환·디지털 헬스 솔루션 전문 글로벌 의료기기 기업으로, 안정적 소모성 매출과 꾸준한 자본 환원이 특징입니다. RMD 주가·전망·실적·관련주·매출 정리.
📚 Related Investment Guides
2026년 미국 배당귀족(Dividend Aristocrats) 완전 가이드
S&P 500 소속, 25년 이상 연속 배당 인상한 배당귀족주 69개 전체 리스트. 섹터별 분포, 배당수익률 순위, NOBL ETF 비교까지 한눈에.
미국주식 세금 총정리 2026 — 초보자를 위한 계산법과 절세 전략
2026년 미국주식 세금 총정리. 양도소득세 22% 계산법, 배당세 15% 원천징수, 손익통산, 절세 전략까지. 실제 금액 시뮬레이션과 세금 계산기로 내 세금을 직접 확인해보세요.

FAQ

What kind of company is 레스메드(RMD)?

레스메드(RMD) belongs to the Healthcare sector and operates in the Medical Instruments & Supplies industry.

What is the market cap of RMD?

The market cap of RMD is approximately $28.3B, ranking 487 within its sector.

Does RMD pay dividends?

RMD has a dividend yield of approximately 1.25%, with an annual dividend of $2.43.

What is the P/E ratio of RMD?

RMD has a P/E ratio of approximately 18.8x, which can be used to assess its valuation relative to the Healthcare sector average.

What is the 52-week high and low for RMD?

RMD has recorded a 52-week high of $293.81 and a low of $180.26.

시황 · 실적발표 · 매수매도 신호, 가장 먼저 받아보세요 🔔 구독

면책조항: 본 콘텐츠는 참고 자료이며 투자 권유가 아닙니다. 모든 투자의 책임은 투자자 본인에게 있습니다.